Tags : pomalidomide

Janssen’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone

Tuba Khan July 13, 2021

Shots: The approval is based on P-III APOLLO study evaluating Darzalex Faspro (SC) + pomalidomide & dexamethasone (Pd) vs Pd alone in 304 patients with RRMM who have received at […]readmore

Regulatory

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for

Tuba Khan July 11, 2019

Shots: The approval is based on P-III OPTIMISMM study results assessing Pomalyst + bortezomib and dexamethasone vs bortezomib + dexamethasone in 559 patients in a ratio (1:1) with 2L+ MM […]readmore

Tags : pomalidomide

Janssen’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : pomalidomide

Janssen’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) + Pomalidomide and Dexamethasone

﻿Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Celgene’s Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada’s Approval for